SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Brambilla Elisabeth)
 

Sökning: WFRF:(Brambilla Elisabeth) > The Promises and Ch...

  • Sholl, LynetteBrigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA. (författare)

The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker : A Perspective from the International Association for the Study of Lung Cancer Pathology Committee

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • ELSEVIER SCIENCE INC,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-422776
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422776URI
  • https://doi.org/10.1016/j.jtho.2020.05.019DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:for swepub-publicationtype

Anmärkningar

  • Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients with NSCLC and have led to unprecedented improvements in response rates and survival in a subset of patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to considerable immune-related adverse events. Therefore, patient selection must be optimized through the use of relevant biomarkers. Programmed death-ligand 1 protein expression by immunohistochemistry is widely used today for the selection of programmed cell death protein 1 inhibitor therapy in patients with NSCLC; however, this approach lacks robust sensitivity and specificity for predicting response. Tumor mutation burden (TMB), or the number of somatic mutations derived from next-generation sequencing techniques, has been widely explored as an alternative or complementary biomarker for response to ICIs. In theory, a higher TMB increases the probability of tumor neoantigen production and therefore, the likelihood of immune recognition and tumor cell killing. Although TMB alone is a simplistic surrogate of this complex interplay, it is a quantitative variable that can be relatively readily measured using currently available sequencing techniques. A large number of clinical trials and retrospective analyses, employing both tumor and blood-based sequencing tools, have evaluated the performance of TMB as a predictive biomarker, and in many cases reveal a correlation between high TMB and ICI response rates and progression-free survival. Many challenges remain before the implementation of TMB as a biomarker in clinical practice. These include the following: (1) identification of therapies whose response is best informed by TMB status; (2) robust definition of a predictive TMB cut point; (3) acceptable sequencing panel size and design; and (4) the need for robust technical and informatic rigor to generate precise and accurate TMB measurements across different laboratories. Finally, effective prediction of response to ICI therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system. This perspective piece will review the current clinical evidence for TMB as a biomarker and address the technical sequencing considerations and ongoing challenges in the use of TMB in routine practice. (c) 2020 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hirsch, Fred R.Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA.;Mt Sinai Hlth Syst, Icahn Sch Med, New York, NY USA. (författare)
  • Hwang, DavidSunnybrook Hlth Sci Ctr, Dept Lab Med & Mol Diagnost, Toronto, ON, Canada. (författare)
  • Botling, JohanUppsala universitet,Klinisk och experimentell patologi,Science for Life Laboratory, SciLifeLab,Johan Botling(Swepub:uu)johanbot (författare)
  • Lopez-Rios, FernandoHM Hosp, Pathol Lab Dianas Terapeut, Madrid, Spain. (författare)
  • Bubendorf, LukasUniv Hosp Basel, Inst Pathol, Basel, Switzerland. (författare)
  • Mino-Kenudson, MariMassachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. (författare)
  • Roden, Anja C.Mayo Clin, Dept Pathol, Rochester, MN USA. (författare)
  • Beasley, Mary BethMt Sinai Hlth Syst, Icahn Sch Med, New York, NY USA. (författare)
  • Borczuk, AlainWeill Cornell Med, Dept Pathol, New York, NY USA. (författare)
  • Brambilla, ElisabethUniv Grenoble Alpes, Grenoble, France. (författare)
  • Chen, GangFudan Univ, Zhongshan Hosp, Shanghai, Peoples R China. (författare)
  • Chou, Teh-YingTaipei Vet Gen Hosp, Taipei, Taiwan. (författare)
  • Chung, Jin-HaengSeoul Natl Univ, Bundang Hosp, Seoul, South Korea. (författare)
  • Cooper, Wendy A.Royal Prince Alfred Hosp, Camperdown, NSW, Australia. (författare)
  • Dacic, SanjaUniv Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. (författare)
  • Lantuejoul, SylvieUniv Grenoble Alpes, Grenoble, France.;Ctr Leon Berard Unicancer, Lyon, France. (författare)
  • Jain, DeepaliAll India Inst Med Sci, New Delhi, India. (författare)
  • Lin, DongmeiPeking Univ Canc Hosp & Inst, Dept Pathol, Beijing, Peoples R China. (författare)
  • Minami, YukoIbarakihigashi Natl Hosp, Tokai, Ibaraki, Japan. (författare)
  • Moreira, AndreWeill Cornell Med, Dept Pathol, New York, NY USA. (författare)
  • Nicholson, Andrew G.Royal Brompton & Harefield NHS Fdn Trust, London, England.;Imperial Coll, Natl Heart & Lung Inst, London, England. (författare)
  • Noguchi, MasayukiUniv Tsukuba, Tsukuba, Ibaraki, Japan. (författare)
  • Papotti, MauroUniv Turin, Dept Oncol, Turin, Italy. (författare)
  • Pelosi, GiuseppeUniv Milan, Milan, Italy.;Ist Ricovero & Cura Carattere Sci MultiMed, Dept Oncol & Hematooncol, Milan, Italy. (författare)
  • Poleri, ClaudiaOggice Pathol Consultants, Buenos Aires, DF, Argentina. (författare)
  • Rekhtman, NatashaMem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. (författare)
  • Tsao, Ming-SoundUniv Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada. (författare)
  • Thunnissen, ErikVrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands. (författare)
  • Travis, WilliamMem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA. (författare)
  • Yatabe, YasushiNatl Canc Ctr, Tokyo, Japan. (författare)
  • Yoshida, AkihikoNatl Canc Ctr, Tokyo, Japan. (författare)
  • Daigneault, Jillian B.Int Assoc Study Lung Canc, Aurora, CT USA. (författare)
  • Zehir, AhmetOggice Pathol Consultants, Buenos Aires, DF, Argentina. (författare)
  • Peters, SolangeLausanne Univ, Ctr Hosp Univ Vaudois, Oncol Dept, Lausanne, Switzerland. (författare)
  • Wistuba, Ignacio I.Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. (författare)
  • Kerr, Keith M.Aberdffn Royal Infirm, Dept Pathol, Aberdffn, Scotland. (författare)
  • Longshore, John W.Atrium Hlth, Carolinas Pathol Grp, Charlotte, NC USA. (författare)
  • Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.;Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.Tisch Canc Inst, Ctr Thorac Oncol, New York, NY USA.;Mt Sinai Hlth Syst, Icahn Sch Med, New York, NY USA. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Thoracic Oncology: ELSEVIER SCIENCE INC15:9, s. 1409-14241556-08641556-1380

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy